Protalix 2026 Revenue Guidance Surpasses Expectations Despite FY25 Miss

Key Facts

1Protalix BioTherapeutics reported weaker than expected FY25 financial results.

2The company issued robust FY26 revenue guidance of $78–83 million, well above market consensus.

3Growth is centered on Elfabrio’s EU approval and its competitive advantage of once-every-4-weeks dosing.

Protalix BioTherapeutics (PLX) reported financial results for the full year 2025 that fell short of market expectations, but its optimistic outlook for 2026 has captured investor attention. The company issued robust revenue guidance for 2026 ranging between $78 million and $83 million, significantly exceeding current market consensus. This anticipated growth is primarily driven by the commercial rollout of Elfabrio, particularly following its regulatory approvals in the European Union. Elfabrio maintains a competitive edge due to its convenient dosing schedule of once every four weeks, which is expected to bolster market share. Furthermore, the partnership with Chiesi Global Rare Diseases continues to support the company’s long-term growth strategy through key milestones. Investors appear to be looking past the short-term revenue miss in favor of the strong growth catalysts projected for the coming year.

Open on chart